Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · NovoCure Ltd (NVCR)

Novocure Q3 revenue rises 16% to $193.4 million; raises 2026 guidance

Positive Impact 4 of 5 earnings Written later

Novocure reported third quarter 2026 net revenues of $193.4 million, up 16% from a year earlier, and a net loss of $10.4 million, or $0.09 per share, narrowed from $37.3 million a year earlier. The company raised its full-year 2026 guidance for net revenue and adjusted EBITDA, which gives shareholders a higher outlook than before the quarter.

Key points

  • Q3 2026 net revenues were $193.4 million, up 16% year over year, driven by 19% global active patient growth.
  • Net loss was $10.4 million ($0.09 per share) versus $37.3 million ($0.33 per share) in Q3 2025; adjusted EBITDA was $15.7 million versus a $3.0 million loss.
  • 2026 net revenue guidance was raised to $736 million to $743 million from $710 million to $725 million.
  • 2026 adjusted EBITDA guidance was raised to $24 million to $34 million from $0 million to $15 million.

The filing

CompanyNovoCure Ltd (NVCR)
Form8-K, current report
Filed with the SECOct 29, 2026, 7:00 AM ET
Accession number0001645113-26-000081

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.